Navigation Links
Resverlogix Activates First Site for ASSURE 1 Clinical Trial
Date:2/25/2010

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to vision to be a leader in the research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation stat
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Resverlogix Completes Patient Recruitment for ASSERT Trial
2. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
3. Resverlogix Presenting at Biotech Showcase
4. Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
5. Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
6. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
7. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
8. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
9. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
10. Resverlogix Provides Quarterly Update
11. Resverlogix Board of Directors Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... California (PRWEB) August 20, 2014 ... develop and apply the most complete climate and ... and demanding climate change issues. , Eight national ... forces with the National Center for Atmospheric Research, ... the new effort. Other participating national laboratories include ...
(Date:8/20/2014)... 20, 2014  PAREXEL International Corporation (NASDAQ: ... at the Baird Healthcare Conference in New York.  ... Officer, will be making a presentation on PAREXEL and ... Sept. 3, 2014. A live webcast of ... of PAREXEL,s website at www.PAREXEL.com in the ...
(Date:8/20/2014)... Not long ago, it was more or ... late in the development cycle – even after the ... suggest that, like many things GxP, expectations for early ... multiple drug sponsors have been required by authorities to ... phase I/II. It’s not only clinical trial material containers ...
(Date:8/20/2014)... could improve the health of your heart, researchers have ... used a standard TENS machine like those designed to ... tragus, the small raised flap at the front of ... , The stimulation changed the influence of the nervous ... that can drive failing hearts too hard. , Professor ...
Breaking Biology Technology:New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3PAREXEL International To Present At Baird Healthcare Conference 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2'Tickling' your ear could be good for your heart 2
... Institute of Standards and Technology (NIST) may have ... of computer memory now under development. The work, ... University (GMU), aims to optimize nanowire-based charge-trapping memory ... computers and cell phones that can operate for ...
... DIEGO, May 25, 2011 Anadys Pharmaceuticals, Inc. (Nasdaq: ... for the treatment of hepatitis C, announced today that it ... ANA773, the Company,s oral immuno-modulator that acts via the TLR-7 ... Annual Meeting in Chicago, IL.  The data from the completed ...
... 2011 WaferGen Biosystems, Inc. (OTCBB:WGBS), a leading ... it has entered into definitive agreements with three ... LLC, Deerfield Management and Merlin Nexus, and certain ... $30.4 million private placement financing of equity and ...
Cached Biology Technology:NIST 'nanowire' measurements could improve computer memory 2Anadys Highlights ANA773 Data to be Presented at ASCO 2Anadys Highlights ANA773 Data to be Presented at ASCO 3Anadys Highlights ANA773 Data to be Presented at ASCO 4WaferGen Announces $30 Million Financing 2WaferGen Announces $30 Million Financing 3WaferGen Announces $30 Million Financing 4
(Date:8/20/2014)... , Aug. 20, 2014 /CNW/ -  Issue ... warning and can quickly become life threatening for some children. ... many as 1.2 million Canadians have food allergies and this ... per cent of children are estimated to have food allergies.  ... from mild skin irritations and hives to breathing difficulties and ...
(Date:8/20/2014)... University, the Wellcome Trust Sanger Institute and the Swiss ... Mycobacterium pinnipedii from skeletons found in Peru which ... a relative of the TB bacterium that affects seals ... researchers assume that seals carried the pathogens from Africa ... was unexpected" comments Sebastien Gagneux, from the Swiss Tropical ...
(Date:8/20/2014)... are visible in in this image of the Para ... these were most likely intentionally set in order to ... forest or stand of trees where the land is ... include conversion of forestland to farms, ranches, or urban ... green of the Amazon Rainforest in the middle of ...
Breaking Biology News(10 mins):Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3
... researchers are among a select group of scientists from ... National Cancer Institute (NCI) for their quest to answer ... Professor and Chair of Oncological Sciences and Ross Cagan, ... received the NCI,s new "Provocative Questions" grant, which was ...
... 2012 Novetta Solutions, LLC (Novetta), a portfolio ... acquisition of International Biometric Group, LLC (IBG). Novetta ... within the National Security community and other organizations ... established in March 2012 through the merger of ...
... can play a key role in feeding people and restoring their ... during their little-known involvement in the liberation of Bergen-Belsen at the ... a historical research paper published in the October issue of the ... been written about the role of the armed forces and medical ...
Cached Biology News:Mount Sinai researchers awarded 'Provocative Questions' grant from National Cancer Institute 2Mount Sinai researchers awarded 'Provocative Questions' grant from National Cancer Institute 3Novetta Solutions Acquires International Biometric Group, LLC 2Novetta Solutions Acquires International Biometric Group, LLC 3Bergen-Belsen lessons underline vital role that nurses can play in patient feeding 2Bergen-Belsen lessons underline vital role that nurses can play in patient feeding 3
... 94kDa ultra-pure recombinant thermostable DNA polymerase obtained ... DNA polymerase gene in E. coli, Concentration: ... of Thermo Fisher Scientific, the world leader ... customers to make the world healthier, cleaner ...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
Collected at a certified USDA establishment located within the United States. All final processing is done by Quad Five employees....
... is a thermostable DNA polymerase derived ... at temperatures above 70°C, it was ... PCR and remains the predominant enzyme ... an intrinsic 5'?3' structure-dependent exonuclease activity, ...
Biology Products: